| Title |
Clinical trials of CAR-T cells in China
|
|---|---|
| Published in |
Journal of Hematology & Oncology, October 2017
|
| DOI | 10.1186/s13045-017-0535-7 |
| Pubmed ID | |
| Authors |
Bingshan Liu, Yongping Song, Delong Liu |
| Abstract |
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China. |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 94 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 19 | 20% |
| Researcher | 14 | 15% |
| Student > Ph. D. Student | 11 | 12% |
| Student > Master | 11 | 12% |
| Other | 8 | 9% |
| Other | 11 | 12% |
| Unknown | 20 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 17% |
| Biochemistry, Genetics and Molecular Biology | 16 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Immunology and Microbiology | 8 | 9% |
| Agricultural and Biological Sciences | 8 | 9% |
| Other | 14 | 15% |
| Unknown | 22 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2019.
All research outputs
#4,440,157
of 23,923,788 outputs
Outputs from Journal of Hematology & Oncology
#350
of 1,233 outputs
Outputs of similar age
#78,387
of 330,917 outputs
Outputs of similar age from Journal of Hematology & Oncology
#6
of 15 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,233 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,917 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.